“Drugs to avoid” to improve quality use of medicines: how is Australia faring?

References

• Shamliyan TA, Kane RL. Drug-related harms in hospitalized Medicare beneficiaries: results from the healthcare cost and utilization project, 2000–2008. J Pat Saf. 2016;12:89–107.
   PubMed Web of Science ®Google Scholar
• Zhang HW, Du W, Gnjidic D, Chong S, Glasgow N. Trends in adverse drug reaction-related hospitalisations over 13 years in New South Wales, Australia. Intern Med J. 2019;49:84–93.
   PubMed Web of Science ®Google Scholar
• Pharmaceutical Society of Australia. Medicine Safety: Take Care. Canberra: PSA; 2019. Accessed 23 June 2021.
   Google Scholar
• Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. Tools for assessment of the appropriateness of prescribing and association with patient-related outcomes: a systematic review. Drugs Aging. 2018;35:43–60.
   PubMed Web of Science ®Google Scholar
• Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahony D. STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert Doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46:72–83.
   PubMed Web of Science ®Google Scholar
• Redaction P. How a review in Prescrire is produced. 2008. https://www.prescrire.org/docus/howreviewsproduced.pdf. Accessed 27 June 2021.
   Google Scholar
• Hwang TJ, Ross JS, Vokinger KN, Kesselheim AS. Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study. 2020;371:m3434.
   Google Scholar
• Wieseler B, McGauran N, Kaiser T. New drugs: where did we go wrong and what can we do better? BMJ-Br Med J. 2019;366:8.
   Web of Science ®Google Scholar
• Bruce CS, Brhlikova P, Heath J, McGettigan P. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: a cross-sectional study of products authorised 2011–2018. PLos Med. 2019;16:30.
   Web of Science ®Google Scholar
• Naci H, Davis C, Savovic J, Higgins JPT, Sterne JAC, Gyawali B, et al. Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014–16: cross sectional analysis. BMJ-Br Med J. 2019;366:17.
   Web of Science ®Google Scholar
• Light DW, Lexchin JR. Pharmaceuticals as a market for “lemons”: Theory and practice. Soc Sci Med. 2021;268:7.
   Web of Science ®Google Scholar
• Davis C, Naci H, Gurpinar E, Poplavska E, Pinto A, Aggarwal A. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009–13. BMJ-Br Med J. 2017;359:13.
   Web of Science ®Google Scholar
• Prescrire Redaction. Towards better patient care: drugs to avoid in 2019. Pescrire Int. 2019;28:1–10.
   Google Scholar
• Vitry AI, Shin NH, Vitre P. Assessment of the therapeutic value of new medicines marketed in Australia. J Pharm Policy Pract. 2013;6:2.
   PubMedGoogle Scholar
• Australian Government, Department of Health, Therapeutic Goods Administration. Australian Register of Therapeutic Goods Canberra 2018. https://www.tga.gov.au/australian-register-therapeutic-goods. Accessed 23 June 2021.
   Google Scholar
• Australian Government, Department of Health. The Pharmaceutical Benefits Scheme. 2019. http://www.pbs.gov.au/pbs/home;jsessionid=1ck9ip7ddiup5eeycglapqnjp. Accessed 23 June 2021.
   Google Scholar
• Australian Government, Department of Health. Australian Statistics on Medicines 2015. 2016. http://www.pbs.gov.au/info/statistics/asm/asm-2015. Accessed 23 June 2021.
   Google Scholar
• Pharmaceutical Benefits Scheme. PBS Expenditure and Prescriptions 2019. https://www.pbs.gov.au/info/statistics/expenditure-prescriptions/pbs-expenditure-and-prescriptions. Accessed 23 June 2021.
   Google Scholar
• Drug Utilisation Sub-Committee. Medicines for the treatment of diabetes Australian Government, Department of Health; 2017. https://www.pbs.gov.au/pbs/industry/listing/participants/public-release-docs/2017-02/medicines-diabetes-feb-2017. Accessed 23 June 2021.
   Google Scholar
• Drug Utilisation Sub-Committee. Medicines for Alzheimer disease. 2016. https://www.pbs.gov.au/pbs/industry/listing/participants/public-release-docs/2016-02/medicines-for-alzheimer-disease-2016-02. Accessed 23 June 2021.
   Google Scholar
• PBS Information Management Section, Department of Health. Expenditure and Prescriptions Twelve Months to 30 June 2018. 2018. https://www.pbs.gov.au/statistics/expenditure-prescriptions/2017-2018/expenditure-and-prescriptions-twelve-months-to-30-june-2018.pdf. Accessed 23 June 2021.
   Google Scholar
• Drug Utilisation Sub-Committee. Osteoporosis medicines. 2016. https://www.pbs.gov.au/pbs/industry/listing/participants/public-release-docs/2016-09/medicines-osteoporosis-2016-09. Accessed 23 June 2021.
   Google Scholar
• Shukla N, Moore K, Gabb G. Olmesartan-associated duodenal villous atrophy, an emerging clinical issue. Intern Med J. 2020;50:624–626.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. 2013. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-approves-label-changes-include-intestinal-problems-sprue. Accessed 2021 6 June
   Google Scholar
• The Royal Australian College of General Practitioners. General practice management of type 2 diabetes 2016–18. 2016. https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/5d3298b2-abf3-487e-9d5e-0558566fc242.pdf. Accessed 23 June 2021.
   Google Scholar
• Curtis HJ, Dennis JM, Shields BM, Walker AJ, Bacon S, Hattersley AT, et al. Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017. Diabetes Obes Metab. 2018;20:2159–2168.
   PubMed Web of Science ®Google Scholar
• Montvida O, Shaw J, Atherton JJ, Stringer F, Paul SK. Long-term trends in antidiabetes drug usage in the US: real-world evidence in patients newly diagnosed with type 2 diabetes. Diabetes Care. 2018;41:69–78.
   PubMed Web of Science ®Google Scholar
• Le Pen C, Bauduceau B, Ansolabehere X, Troubat A, Bineau S, Ripert M, et al. Penetration rates of new pharmaceutical products in Europe: a comparative study of several classes recently launched in type-2 diabetes. Ann Endocrinol. 2021;82:99–106.
   PubMed Web of Science ®Google Scholar
• Inoue K, Tsugawa Y, Mangione CM, Duru OK. Association between industry payments and prescriptions of long-acting insulin: an observational study with propensity score matching. PLos Med. 2021;18:14.
   Web of Science ®Google Scholar
• Fleischman W, Agrawal S, King M, Venkatesh AK, Krumholz HM, McKee D, et al. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study. BMJ-Br Med J. 2016;354:8.
   Web of Science ®Google Scholar
• Lipska KJ, Krumholz HM. Is hemoglobin A1c the right outcome for studies of diabetes? JAMA. 2017;317:1017–1018.
   PubMed Web of Science ®Google Scholar
• Farcas A, Mahalean A, Bulik NB, Leucuta D, Mogosan C. New safety signals assessed by the Pharmacovigilance Risk Assessment Committee at EU level in 2014–2017. Expert Rev Clin Pharmacol. 2018;11:1045–1051.
   PubMed Web of Science ®Google Scholar
• Haute Autorite de Santė. Insufficient clinical benefit: these medicinal products no longer have a role in the treatment of Alzheimer’s disease. 2016. https://www.has-sante.fr/portail/jcms/c_2681003/en/ebixa-memantine-non-competitive-nmda-receptor-antagonist. Accessed 23 June 2021.
   Google Scholar
• Laroche ML, Perault-Pochat MC, Ingrand I, Merle L, Kreft-Jais C, Castot-Villepelet A, et al. Adverse drug reactions in patients with Alzheimer’s disease and related dementia in France: a national multicentre cross-sectional study. Pharmacoepidemiol Drug Saf. 2013;22:952–960.
   PubMed Web of Science ®Google Scholar
• Reeve E, Farrell B, Thompson W, Herrmann N, Sketris I, Magin PJ, et al. Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary. Med J Aust. 2019;210:174–179.
   PubMed Web of Science ®Google Scholar
• Redaction P. Denosumab: immune dysfunction. Prescrire Int. 2018;27:268–269.
   Google Scholar
• Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guañabens N, et al. Discontinuation of Denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. 2017;105:11–17.
   PubMed Web of Science ®Google Scholar
• Australian Government, Department of Health, Therapeutics Goods Administration. Database of Adverse Event Notifications - medicines. 2019. http://apps.tga.gov.au/Prod/daen/daen-entry.aspx. Accessed 23 June 2021.
   Google Scholar
• Therapeutic Guidelines. Depression in adults. 2015. https://tgldcdp.tg.org.au/viewTopic?topicfile=depression#MPS_d1e807. Accessed 23 June 2021.
   Google Scholar
• CredibleMeds. Search for Drugs that Prolong QT & induce Torsades de Pointes (TdP). 2019. https://www.crediblemeds.org/drugsearch. Accessed 23 June 2021.
   Google Scholar
• Organisation for Economic Co-operation and Development (OECD). Health at a Glance 2019 : OECD Indicators. Pharmaceutical consumption. 2019. https://www.oecd-ilibrary.org/sites/43146d4b-en/index.html?itemId=/content/component/43146d4b-en. Accessed 22 June 2021.
   Google Scholar
• de Vries YA, Roest AM, de Jonge P, Cuijpers P, Munafo MR, Bastiaansen JA. The cumulative effect of reporting and citation biases on the apparent efficacy of treatments: the case of depression. Psychol Med. 2018;48:2453–2455.
   PubMed Web of Science ®Google Scholar
• Whitely M, Raven M, Jureidini J. Antidepressant prescribing and suicide/self-harm by young Australians: regulatory warnings, contradictory advice, and long-term trends. Front Psychiatry. 2020;11:14.
   PubMed Web of Science ®Google Scholar
• Redaction P. Tolcapone: in Parkinson’s disease: unacceptable risk of severe hepatitis. Prescrire Int. 2006;15:54–57.
   PubMedGoogle Scholar
• Australian Governement DoH. Therapeutic Goods Administration, Cramps, quinine and thrombocytopenia. Med Safety Update. 2011;2:1.
   Google Scholar
• Lexchin J. Canadian status of “drugs to avoid” in 2017: a descriptive analysis. CMAJ Open. 2018;6:E430–E435.
   PubMedGoogle Scholar
• Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016;14:10.
   PubMed Web of Science ®Google Scholar
• Perry LT, Bhasale A, Fabbri A, Lexchin J, Puil L, Joarder M, et al. Comparative Analysis of Medicines Safety Advisories Released by Australia, Canada, the United States, and the United KingdomComparative Analysis of Medicines Safety Advisories Released by Australia, Canada, the US, and the UKLetters. JAMA Internal Medicine. 2019.
   PubMed Web of Science ®Google Scholar
• Naci H, Cylus J, Vandoros S, Sato A, Perampaladas K. Raising the bar for market authorisation of new drugs. Br Med J. 2012;345:5.
   Google Scholar
• Naci H, Lehman R, Wouters OJ, Goldacre B, Yudkin JS. Rethinking the appraisal and approval of drugs for type 2 diabetes. BMJ. 2015;351:5.
   Google Scholar
• Erviti J, Gorricho J, Saiz LC, Perry T, Wright JM. Rethinking the appraisal and approval of drugs for fracture prevention. Front Pharmacol. 2017;8:6.
   PubMed Web of Science ®Google Scholar
• Australian Government, Department of Health. Quality Use of Medicines (QUM). 2019. https://www.health.gov.au/internet/main/publishing.nsf/Content/nmp-quality.htm. Accessed 23 June 2021.
   Google Scholar
• Australian Commission on Safety and Quality in Health Care. Quality Use of Medicines and Medicines Safety Discussion Paper. 2020. Accessed 23 June 2021.
   Google Scholar